MedTrace Logo

A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01475292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-05-03

No results posted yet for this study

Summary

RV568 is being developed as a possible treatment of diseases such as smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma.

The main purpose of this study is to examine the safety of RV568 in COPD patients. Two dose strengths of RV568 and a placebo will be tested in this study, which will be given by inhaling a liquid suspension from a nebuliser once a day for 2 weeks.

Conditions

Interventions

DRUG

RV568

RV568 50 ug administered via a nebuliser once daily for 14 days

DRUG

RV568

RV568 100 ug administered via a nebuliser once daily for 14 days

DRUG

Placebo

Placebo administered via a nebuliser once daily for 14 days

Sponsors & Collaborators

  • Respivert Ltd

    lead INDUSTRY

Principal Investigators

  • Leonard Siew, MD · Quintiles Drug Research Unit at Guy's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01475292 on ClinicalTrials.gov